Aurobindo Pharma USA Initiates Class II Recall of Amazon Basic Care Acetaminophen Due to cGMP Deviations
Aurobindo Pharma USA Inc. has initiated a voluntary Class II recall of 4,608 bottles of Amazon Basic Care Acetaminophen Tablets, 325 mg, due to confirmed consumer complaints of tablet discoloration, indicating cGMP deviations. This nationwide recall highlights critical quality control vulnerabilities for both manufacturers and private label distributors, necessitating immediate supply chain risk assessment and robust quality assurance protocols for procurement and regulatory teams.
What Prompted the Recall: cGMP Deviations and Product Quality Concerns
Aurobindo Pharma USA Inc., based in East Windsor, New Jersey, has initiated a voluntary Class II recall for a specific lot of Acetaminophen Tablets, 325 mg, distributed under the Amazon Basic Care brand. The recall, identified as D-0471-2025, was triggered by confirmed consumer complaints detailing tablet discoloration, specifically a brown surface on the tablets. This observation points directly to critical Current Good Manufacturing Practice (cGMP) deviations within the manufacturing process, indicating a failure to maintain product quality and consistency. For procurement directors and regulatory affairs heads, this event underscores the imperative of stringent quality control throughout the manufacturing lifecycle. The presence of discoloration, even if not immediately life-threatening, signals a breakdown in process controls that could compromise product stability, efficacy, or purity. The affected product, from Lot#: AEF124004A with an expiration date of August 31, 2026, represents a tangible risk to consumer trust and brand integrity. Businesses sourcing similar over-the-counter (OTC) medications must immediately review their supplier audit programs to ensure that cGMP compliance extends beyond initial qualification, encompassing ongoing monitoring of production processes and robust complaint handling mechanisms to detect and address such deviations proactively.
Recalling Entity and Product Profile: Aurobindo Pharma USA's Acetaminophen Market Presence
The recalling firm, Aurobindo Pharma USA Inc., located at 279 Princeton Hightstown Rd, East Windsor, NJ 08520-1401, is responsible for the Acetaminophen Tablets, 325 mg. This product is a human OTC drug, packaged in 100-count bottles, identified by NDC 72288-405-10. While Aurobindo Pharma USA Inc. is the recalling entity, the product is prominently distributed by Amazon.com Services LLC, 410 Terry Avenue N., Seattle, WA 98109, under their private label brand, AMAZON BASIC CARE ACETAMINOPHEN. This highlights a common industry practice where major retailers leverage established manufacturers for their own branded products. For business development executives and supply chain VPs, this dual branding scenario presents a complex risk profile. The recall directly impacts the reputation of Amazon's private label, a significant player in the retail pharmaceutical space. Understanding the contractual obligations and quality agreements between manufacturers like Aurobindo and distributors like Amazon is crucial. This incident necessitates a review of how quality failures at the manufacturing level can propagate and affect a distributor's brand equity and market position. Companies engaged in private label agreements must ensure their contracts include robust clauses for quality assurance, recall management, and liability to mitigate potential commercial and reputational damage.
Supply Chain Exposure: Nationwide Distribution and Brand Implications for Amazon Basic Care
The affected Acetaminophen Tablets were distributed USA Nationwide, indicating a broad market exposure for the 4,608 bottles subject to this Class II recall. While the specific quantity might seem moderate in the context of national pharmaceutical sales, the nationwide distribution pattern means that the product reached a wide consumer base across the United States. This extensive reach amplifies the potential for consumer complaints and regulatory scrutiny, despite the voluntary nature of the recall initiated by Aurobindo Pharma USA Inc. For procurement directors and supply chain VPs, the nationwide distribution of a product with cGMP deviations underscores the critical importance of end-to-end supply chain visibility and control. The recall of 'AMAZON BASIC CARE ACETAMINOPHEN' directly impacts Amazon.com Services LLC's brand reputation, a key consideration for any company involved in private label manufacturing or distribution. This event serves as a stark reminder that quality issues at any point in the supply chain can have far-reaching commercial consequences, affecting consumer trust and potentially leading to significant financial and logistical burdens associated with product retrieval and remediation. Proactive risk management, including geographic diversification of suppliers and robust contingency planning, becomes indispensable to safeguard market presence.
Regulatory Classification and Business Implications: Navigating Class II Recall Procedures
The FDA has classified this event as a Class II recall, a designation indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification, while less severe than a Class I recall, still demands a comprehensive and timely response from Aurobindo Pharma USA Inc. The recall was firm-initiated and communicated initially via e-mail on May 22, 2025, with the FDA's Center classification occurring on June 17, 2025, and the report date on June 25, 2025. For regulatory affairs heads, understanding the nuances of Class II recalls is vital. This classification necessitates effective communication strategies, efficient product retrieval from the market, and a thorough investigation into the root cause of the cGMP deviations. The FDA's ongoing oversight means that Aurobindo Pharma USA Inc. will be expected to provide a robust corrective and preventive action (CAPA) plan. Failure to adequately address the underlying cGMP issues could lead to further regulatory actions, including potential Warning Letters or import alerts for future products. This incident reinforces the FDA's consistent focus on manufacturing quality across all drug product categories, aligning with the broader regulatory environment where events like Essential Wellness Pharma's sterility failures highlight persistent challenges in pharmaceutical compliance.